Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$20.95 -1.4%	$20.01	$13.40 ▼ $25.23	$3.51B	0.64	1.97 million shs	916,896 shs
ADMA ADMA Biologics	$18.12 -0.1%	$20.40	$10.21 ▼ $25.67	$4.33B	0.43	3.69 million shs	1.05 million shs
AKRO Akero Therapeutics	$52.01 +0.3%	$48.44	$21.02 ▼ $58.40	$4.15B	-0.15	1.04 million shs	404,787 shs
ALLO Allogene Therapeutics	$1.19 -0.8%	$1.28	$0.86 ▼ $3.78	$260.29M	0.31	3.26 million shs	1.38 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-0.56%	-5.60%	-1.07%	+31.76%	+34.09%
ADMA ADMA Biologics	+1.45%	+3.07%	-11.21%	-6.74%	+59.12%
AKRO Akero Therapeutics	+0.91%	-5.74%	+2.27%	+29.73%	+131.81%
ALLO Allogene Therapeutics	+1.69%	-3.23%	-5.51%	-13.04%	-44.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.6944 of 5 stars	4.4	3.0	0.0	3.2	4.2	2.5
ADMA ADMA Biologics	4.0975 of 5 stars	3.7	2.0	0.0	2.7	2.5	3.1
AKRO Akero Therapeutics	3.6296 of 5 stars	3.5	1.0	4.7	2.2	0.8	0.0
ALLO Allogene Therapeutics	3.4239 of 5 stars	4.5	1.0	0.0	2.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$27.88	33.32% Upside
ADMA ADMA Biologics	3.33	Buy	$27.67	50.57% Upside
AKRO Akero Therapeutics	3.00	Buy	$82.50	60.19% Upside
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	618.68% Upside

Current Analyst Ratings Breakdown

Latest ADMA, ACAD, AKRO, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00
5/20/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $24.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.65	$0.69 per share	30.30	$4.40 per share	4.75
ADMA ADMA Biologics	$426.45M	10.29	$0.56 per share	33.03	$1.48 per share	12.42
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
ALLO Allogene Therapeutics	$20K	12,850.39	N/A	N/A	$2.01 per share	0.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	15.26	27.51	4.60	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
ADMA ADMA Biologics	$197.67M	$0.85	21.59	26.63	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)

Latest ADMA, ACAD, AKRO, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
ADMA ADMA Biologics	0.22	6.58	3.36
AKRO Akero Therapeutics	0.03	16.80	16.80
ALLO Allogene Therapeutics	N/A	9.71	9.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ADMA ADMA Biologics	75.68%
AKRO Akero Therapeutics	N/A
ALLO Allogene Therapeutics	83.63%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
ADMA ADMA Biologics	3.50%
AKRO Akero Therapeutics	7.07%
ALLO Allogene Therapeutics	13.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable

ADMA, ACAD, AKRO, and ALLO Headlines

Recent News About These Companies

ALLO - Allogene Therapeutics Inc Dividends - Morningstar

June 27, 2025 | morningstar.comM

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

June 22, 2025 | marketbeat.com

Systemic Lupus Erythematosus Pipeline Heats Up as 120+ Companies Advance Cutting-Edge Therapies | DelveInsight

June 18, 2025 | theglobeandmail.com

Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?

June 12, 2025 | zacks.com

Zacks Research Issues Optimistic Forecast for ALLO Earnings

June 6, 2025 | marketbeat.com

All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy

June 4, 2025 | zacks.com

HC Wainwright Issues Optimistic Forecast for ALLO Earnings

June 4, 2025 | marketbeat.com

Q1 Earnings Forecast for ALLO Issued By HC Wainwright

June 3, 2025 | marketbeat.com

Allogene Therapeutics Presents Promising Phase 1 Data for ALLO-316 in Renal Cell Carcinoma

June 2, 2025 | msn.com

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

June 1, 2025 | globenewswire.com

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

May 29, 2025 | seekingalpha.com

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

May 28, 2025 | seekingalpha.com

Allogene shares update on CAR T-cell therapies at ASCO meeting

May 24, 2025 | investing.com

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

May 23, 2025 | globenewswire.com

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

May 22, 2025 | globenewswire.com

Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M

May 22, 2025 | finance.yahoo.com

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff

May 17, 2025 | biopharmadive.comB

Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results

May 15, 2025 | msn.com

Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

May 15, 2025 | zacks.com

Allogene lays off 28% of staff to extend runway amid delays to CAR-T updates

May 14, 2025 | fiercebiotech.comF

Allogene's Q1 Earnings In Line With Estimates, Sales Nil

May 14, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA, ACAD, AKRO, and ALLO Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$20.95 -0.29 (-1.37%)

As of 02:16 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ADMA Biologics NASDAQ:ADMA

$18.12 -0.02 (-0.09%)

As of 03:08 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Akero Therapeutics NASDAQ:AKRO

$52.01 +0.13 (+0.26%)

As of 02:56 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics NASDAQ:ALLO

$1.19 -0.01 (-0.83%)

As of 03:01 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time